p19ARF is induced in response to oncogene activation or during cellular senescence in mouse embryo fibroblasts, triggering p53-dependent and p53-independent cell cycle arrest and apoptosis. We have studied the involvement of human p14ARF as a regulator of p53 activity in normal human skin fibroblasts (NHFs) or WI38 lung embryonic fibroblasts expressing conditional Myc or E2F1 estrogen receptor fusion proteins. Both Myc and E2F1 activation rapidly induced p53 phosphorylation at Ser-15, p53 protein accumulation, and upregulation of the p53 target genes MDM2 and p21. Activation of E2F1 induced p14ARF mRNA and protein levels. In contrast, Myc activation did not induce any significant increase in p14ARF mRNA or protein levels in neither NHFs nor WI38 fibroblasts within 48 h. Myc and E2F1 induced p53 and cell cycle arrest even after silencing of p14ARF using short-interfering RNA. Treatment with the ATM/ATR kinase inhibitor caffeine prevented p53 accumulation upon activation of Myc or E2F1. Our results indicate that p53 phosphorylation, but not p14ARF, plays a major role for the induction of p53 in response to Myc and E2F1 activation in normal human fibroblasts.
Introduction
The tumor suppressor protein p53 is activated by various types of cellular stress, including DNA damage, oncogene activation, hypoxia, and heat shock (for reviews, see Vogelstein et al., 2000; Vousden, 2002) . p53 is a transcription factor that transactivates a set of target genes that control cell cycle progression and cell survival (for a review, see El-Deiry, 1998) . p53 is tightly controlled by the MDM2 regulatory oncoprotein that targets p53 for nuclear export and proteasomal degradation (reviewed in Alarcon-Vargas and Ronai, 2002; Vousden, 2000) . The stability and activity of p53 is regulated by post-translational modifications including phosphorylation and acetylation (reviewed in Prives, 1998) .
p14ARF (p19ARF in mouse) is encoded by an alternative reading frame within the CDKN2A (INK4a/ARF) locus on chromosome 9p21 . This locus also encodes the cyclin-dependent kinase inhibitor p16INK4a (Kamb et al., 1994) . ARF stabilizes p53 by binding to and inhibiting MDM2 (Zhang et al., 1998) . More specifically, ARF interferes with MDM2-mediated polyubiquitination of p53 in vivo (Xirodimas et al., 2001) , in part through inhibition of the ubiquitin ligase activity of MDM2 (Honda and Yasuda, 1999) . Although overexpression of ARF can result in sequestration of MDM2 in some settings , relocalization of MDM2 or stabilization of p53 is not absolutely essential for ARF to activate p53 (Llanos et al., 2001; Korgaonkar et al., 2002) . Studies in mice indicate that both p16INK4a and p19ARF are bona fide tumor suppressors (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001) . p16INK4a induces growth arrest and senescence in human and mouse cells (for a review see, Drayton and Peters, 2002) . p19ARF inhibits cell growth in both a p53-dependent and p53-independent manner Kuo et al., 2003) . p16INK4a is frequently inactivated by homozygous deletion, point mutation, or promotor methylation in human tumors (for a review see, Sharpless and DePinho, 1999) . Likewise, p14ARF is inactivated in many human tumors, often by deletion along with p16INK4a (Sharpless and DePinho, 1999; Sherr and Weber, 2000) .
The c-myc proto-oncogene encodes a transcription factor that heterodimerizes with Max and regulates genes involved in cellular growth, proliferation, differentiation, and apoptosis (for reviews see, Cole and McMahon, 1999; Henriksson et al., 2001) . Myc stimulates cyclin D/cdk4/6 and cyclin E/cdk2 activity, and antagonizes the cdk inhibitors p21 and p27, thus driving the Rb/E2F pathway and S phase entry (Coller et al., 2000; Hermeking et al., 2000; Santoni-Rugiu et al., 2000) . Ectopic overexpression of c-Myc induces p53 and sensitizes cells to both p53-dependent and p53-independent apoptosis in low serum or after growth factor deprivation (Askew et al., 1991; Evan et al., 1992; Hermeking and Eick, 1994) .
The E2F1 transcription factor promotes S phase entry by activating genes involved in DNA replication and cell proliferation (for a review see, Muller and Helin, 2000) .
Like c-Myc, enforced expression of E2F1 results in cell cycle arrest and apoptosis in a p53-dependent manner (Wu and Levine 1994; Kowalik et al., 1995) . In addition, E2F1 also induces p53-independent apoptosis by direct activation of genes such as p73, Apaf-1 (apoptosis protease-activating factor 1) and caspases (Stiewe and Putzer 2000; Moroni et al., 2001; Nahle et al., 2002) .
Oncoproteins such as E2F1 (Inoue et al., 1999) , Ras , Myc , v-abl (Cong et al., 1999) , Raf (Ries et al., 2000) , b-catenin (Damalas et al., 2001) , and E1A (de Stanchina et al., 1998) were shown to induce p53 at least in part by upregulation of p19ARF in mouse embryo fibroblasts (MEFs). These findings led to the conclusion that ARF is critical for the p53 response to activated oncogenes or hyperproliferative signalling, and that ARF-p53-dependent apoptosis could be an important tumor surveillance mechanism to eliminate incipient tumor cells (reviewed in Sherr, 1998) . One possible mechanism by which ARF could 'sense' and respond to oncogene activation is transcriptional activation of ARF by E2F. Mouse and human ARF are transcriptionally upregulated by E2F1 Robertson and Jones, 1998; Inoue et al., 1999; Zhang and Xiong, 1999; Dimri et al., 2000; Parisi et al., 2002) . However, E2F1 and E2F2 appear dispensable for induction of p19ARF in MEFs in response to E1A or oncogenic Ras (Palmero et al., 2002) . Moreover, regulation of ARF differs between human and mouse in that p14ARF is not upregulated during fibroblast senescence in vitro and that p14ARF is not induced by Ras overexpression in human fibroblasts (Ferbeyre et al., 2000; Wei et al., 2001; Brookes et al., 2002; Huot et al., 2002) .
In this study, we asked if Myc and E2F1 stabilize and activate p53 through induction of p14ARF in normal human fibroblasts. To address this question, we have used human fibroblasts that express Myc or E2F1 estrogen receptor fusion proteins (MycER and ERE2F1) (Eilers et al., 1989; Littlewood et al., 1995) . The original MycER fusion protein consists of the hormone binding domain of the human estrogen receptor fused to c-Myc residues 1-435 and is cytoplasmic in the absence of hormone (Eilers et al., 1989) . Both 17-b estradiol (E2) and 4-hydroxytamoxifen (4-HT) activate c-Myc by triggering rapid nuclear translocation of the fusion protein. A modified and improved version denoted MycER TAM (tamoxifen mutant) consists of an estrogen receptor mutant that is responsive only to 4-HT (Littlewood et al., 1995) .
Results

Stabilization of p53 following Myc and E2F1 activation in human fibroblasts
Activation of the MycER fusion protein in normal human foreskin fibroblasts (NHF) with E2 in fullgrowth medium resulted in G2/M cell cycle arrest in a p53-and p21-dependent manner (Felsher and Bishop, 1999; Felsher et al., 2000) , whereas activation of MycER TAM WI38 fibroblasts with 4-HT mainly induced cell death by apoptosis (Hirst and Grandori, 2000) . Activation of ER TAM -E2F1 triggered cell cycle arrest and eventually cell death or senescence as previously reported Lomazzi et al., 2002; Nahle et al., 2002) . In agreement with these previous studies, we found that the MycER and ER TAM -E2F1 fusion proteins are translocated from the cytoplasm to the nucleus following addition of hormone, as demonstrated with ER TAM -E2F1 in Figure 1a . Nuclear Hoechst 33258 staining indicated apoptosis in MycER TAM WI38 cells but not in MycER NHFs (Figure 1b ). This was corroborated by the morphological appearance of the cells following addition of hormone (Figure 1c) . However, a slightly increased number of floating cells were observed in cultures of both MycER NHFs, and MycER E6 NHFs as compared to pBabe control NHFs ( Figure 1c ). NHFs that undergo apoptosis usually do so by rapid deattachment (Chen et al., 2000) . Thus, we believe that Myc activation causes apoptosis in a small fraction of these cells as well.
In order to demonstrate p53 stabilization and activation, cells were treated with E2 or 4-HT to activate MycER and then analysed for p53, MDM2, and p21 protein expression. Figure 2 shows a representative experiment using MycER NHFs. The increase in p53 protein levels was rapid and reached a maximum at 48 h after activation of Myc (Figure 2a, d ). Both MDM2 and p21 were induced with a delayed kinetics compared to p53 but not in NHFs expressing both E6 and Myc (Figure 2a, b) , indicating that their upregulation by Myc was p53-dependent. The increase in the levels of MDM and p21 was clearly detectable after 24 h and reached a plateau after 48 h (Figure 2a ). Control NHFs treated with E2 did not show any significant alterations in p53 nor MDM2 protein levels when normalized to b-actin (Figure 2c ). Stabilization of p53 and induction of its downstream targets MDM2 and p21 were also observed with similar kinetics in MycER TAM and ER TAM -E2F1 WI38 cells (Figure 2e, f) . A striking reduction in the levels of E2F1 at 48 h in asynchronously proliferating MycER NHFs was also observed, presumably a consequence of cell cycle arrest in G2/M (Figure 2a) . We did not observe any major changes in p53 or E2F1 protein levels in control NHFs or MycER E6 NHFs upon addition of E2 (Figure 2b , c).
Myc activation does not markedly induce p14ARF in NHFs
Next, we tested if induction of p53 and p53-dependent cell cycle arrest and apoptosis following Myc or E2F1 were associated with upregulation of p14ARF. Normal human fibroblasts express low levels of p14ARF at the limit of detection. Early passage fibroblasts appear to express higher levels of p14ARF mRNA than later passages (Wei et al., 2001 Figure 2 MycER and ERE2F1 activation induces p53 in human diploid fibroblasts. (a-c) MycER NHFs, MycER E6 NHFs, and pBabe NHFs were activated with E2 (1 mm) for 0, 24, or 48 h as indicated. Whole-cell lysates were prepared from each time point and proteins were detected by Western blotting using antibodies against p53, MDM2, p21, and E2F1. b-actin served as a control for protein loading and integrity. (d) MycER NHFs activated with E2 were harvested at indicated time points and analysed for expression of MDM2, p53, b-actin, and p14ARF. HeLa cell nuclear extracts were used as a positive control for p14ARF. (e, f) ER TAM -E2F1 and MycER TAM WI38 cells were treated with 300 nm 4-HT and whole-cell lysates were prepared after 0, 24, 48 h and subsequently resolved on SDS polyacrylamide gels. Proteins were detected using antibodies against p53, p53 phospho-Ser-15, MDM2, p21, and p14ARF. bactin served as loading control. Note that (e) and (f) are two separate blots p14ARF-independent induction of p53 by Myc and E2F1 MS Lindström and KG Wiman cells did not reveal any increase in p14ARF mRNA expression following Myc activation within the first 48 h (Figure 3b-d) . In contrast, activation of E2F1 caused a rapid and sustained upregulation of p14ARF mRNA, clearly detectable already after 4 h (Figure 3a) , and p14ARF protein within 24 h (Figure 2f ). We also observed an increase in p53 mRNA in MycER NHFs, but not in MycER TAM WI38 cells, after Myc activation (Figure 3b, c) .
p14ARF expression following Myc activation in both types of fibroblasts was also examined by immunofluorescence staining. Myc activation caused homogenous nucleoplasmic p53 and MDM2 staining patterns clearly avoiding nucleoli and without formation of nuclear body-like structures, but all cells remained p14ARF negative at 24 h after Myc activation, as determined by staining with all available p14ARF antibodies (Figure 4a, b, d) . In contrast, induction of p14ARF was readily detected in ER TAM -E2F1 WI38 cells already at 12 h after addition of hormone, and further increased up to 48 h ( Figure 4c ). Prolonged activation of MycER in fullgrowth medium led to the apperance of a few (o 5%) p14ARF-positive cells (Figure 4e ). The fraction of p14ARF-positive cells increased further up to 96 h in culture, at which time point rare outgrowth of p14ARF-positive clones was observed. This did not correlate with p53 stabilization or cell cycle arrest (data not shown), and the p14ARF staining was very weak compared to that of the ER TAM -E2F1 WI38 cells upon E2F1 activation (Figures 4e, 5d ). MycER TAM WI38 cells remained entirely p14ARF negative at all time points. p14ARF induced by E2F1 was localized to nucleoli and 'nucleoplasmic bodies'. No sequestration of MDM2 to nucleoli was observed in ER TAM -E2F1 WI38 cells or in the few MycER NHFs expressing nucleolar p14ARF, in agreement with a previous report (Llanos et al., 2001) . Thus, Myc induced p53 in the absence of a detectable increase in p14ARF expression.
A subset of MycER NHFs underwent aberrant nuclear divisions before ceasing replication, indicating DNA rereplication and failure to complete cytokinesis (Li and Dang, 1999) . Thus, a fraction of MycER NHFs contained multiple nonseparated nuclei (Figure 4d ). Notably, these cells expressed much higher levels of p53 and MDM2 than cells with normal morphology (Figure 4d ). Finally, we also investigated the levels of p14ARF in MycER E6 NHFs that did not express detectable amounts of p53 ( Figure 2b ). These cells expressed higher levels of p14ARF mRNA than control fibroblasts (Figure 3c ), but the p14ARF protein levels were strikingly lower than in human tumor cell lines with mutant p53, although p14ARF-positive cells was Myc and E2F1 stabilize p53 in the presence of p14ARF siRNA
To further investigate the role of p14ARF for induction of p53 in response to Myc activation, we used shortinterfering RNA (siRNA) to silence p14ARF expression following Myc activation. We used a fluorescein isothiocyanate (FITC)-conjugated siRNA approximately corresponding to sequences derived from the 3 0 end of exon 1b and the 5 0 region of the common CDKN2A exon 2 (approximately corresponding to amino acids 62-69 in p14ARF). We have not observed silencing of p16INK4a protein expression in Saos-2 osteosarcoma cells nor NHFs using this duplex, arguing that it is p14ARF specific. Cycloheximide treatement of HeLa and H1299 cell lines that both express high levels of nuclear and nucleolar p14ARF indicated that the preexisting protein pool was stable because p14ARF was found in the nucleolus of many cells up to 18 h after treatment. We evaluated the uptake and efficacy of the p14ARF siRNA 48 h after transfection. Almost complete transfer of the siRNA was observed. The FITClabelled siRNA duplex was mainly localized in cytoplasmic vesicle-like structures in a dotty pattern in proximity to the nuclear membrane, the perinuclear space (Figure 5a, b) . In addition, a diffuse nuclear and cytoplasmic staining was present in many cells (Figure 5a, b) . Efficient silencing of p14ARF protein expression was obtained in both HeLa and H1299 cells, although some cells expressed low but detectable levels of p14ARF (Figure 5a , b). The p14ARF siRNA did not reduce p19ARF expression in p53 null MEFs, presumably due to the sequence divergence between mouse and human ARF (Figure 5c ).
Next, we treated MycER NHFs with p14ARF siRNA and added E2 to activate Myc 12 h later. The cells were analysed after another 48 h. No p14ARF-positive cells were detected at this time point (Figure 5e ). We did not observe any significant changes in p53 protein levels in siRNA-treated cells compared to control cells using immunostaining or Western blotting (Figure 5e TAM WI38 activated with 4-HT in the presence of serum were double stained using p53 polyclonal and mouse p14ARF monoclonals. MycER TAM WI38 cells remained strictly p14ARF negative after Myc activation in full-growth medium. (c) WI38 cells expressing ER TAM -E2F1 were stained for p14ARF and p53. Cells expressing ER TAM -E2F1 showed strong nucleolar and some nucleoplasmic staining for p14ARF along with an increased nucleoplasmic staining for endogenous p53. However, p53 stabilization was also observed independently of p14ARF expression in a few cells. (d) MycER NHFs were treated with E2 (1 mm) for 48 h and stained with antibodies against p53 (DO1) and MDM2 (SMP14). Corresponding phase contrast images show the morphology of the fibroblasts with typical Myc-induced nuclear abnormalities. Note the elevated levels of p53 and MDM2 in cells with multiple nuclei (upper panel) or in the bi-lobed cell in the lower panel. (e) MycER NHFs were treated with E2 (1 mm) or mock-treated with EtOH for 48 h and stained for p14ARF. Most cells remained p14ARF negative, but a few p14ARF-positive cells were detected in some image fields as indicated by arrows. (f) MycER E6 NHFs were activated with E2 and stained for p14ARF. Positive cells were frequently encountered, but the staining intensity was very low compared to that of HeLa and H1299 cells (see also Figure 5a -c). Magnification Â 63 p14ARF-independent induction of p53 by Myc and E2F1 MS Lindström and KG Wiman siRNA did not result in any major changes in p53 protein levels upon E2F1 activation as compared to cells treated with control siRNA oligo, clearly indicating that p14ARF is not a key mediator of p53 stabilization (Figure 5f , right panel). However, we observed a small increase in cells accumulating in the G2 phase of the cell cycle ( Figure 5 (g) . Densitometry analysis confirmed that the p53 levels were reduced by less than 15% in MycER NHFs and less than 25% in ER TAM -E2F1 WI38 cells treated with p14ARF siRNA after normalization to b-actin. Complete silencing of p14ARF was not achieved in these primary fibroblasts indicating that p14ARF RNAi is not as efficient in these cells as in HeLa and H1299 tumor cell lines, despite similar uptake Figure 5 Silencing of p14ARF using siRNA in human tumor cell lines and primary fibroblasts. (a, b) HeLa and H1299 cells grown on coverslips in six-well plates were transfected with 0.5 mg of control siRNA or the same amount of p14ARF-specific siRNA and analysed for p14ARF expression after 48 h. Cells were stained with p14ARF monoclonal Ab2 followed by a Texas Red secondary antimouse Ig antibody. Efficient silencing of p14ARF protein was observed in both the cell lines, although some positive cells were found, serving as internal control for the staining procedure. (c) Transfection of p14ARF siRNA or control siRNA in p53 null MEFs expressing high levels of p19ARF did not cause downregulation of p19ARF. Mouse p19ARF was visualized using polyclonal Ab80 followed by a goat anti-rabbit polyclonal antibody conjugated with Texas Red. (d) Transfection of p14ARF siRNA prevented p14ARF induction in ER TAM -E2F1 WI38 cells when analysed 48 h after addition of hormone. (e) MycER NHFs were transfected with control or p14ARF siRNA and activated with E2 12 h after transfection. Cells were double stained for p53 (AMCA) and p14ARF (Texas Red). (f) Western blot analysis of activated MycER NHFs or ER TAM -E2F1 WI38 fibroblasts treated with control siRNA or p14ARF siRNA. Cells were activated with E2/4-HT 12 h after transfection and analysed for p53, b-actin and p14ARF protein expression using antibodies as described in Figure 2 . (g) E2/4-HT treated MycER NHFs, ER TAM -E2F1 WI38 and control NHFs transfected with siRNA control and p14ARF siRNA were analysed for cell cycle distribution using propidium iodide (PI) staining 48 h after activation p14ARF-independent induction of p53 by Myc and E2F1 MS Lindström and KG Wiman of the siRNA oligo (Figure 5f , right panel). Unfortunately, we were not able to evaluate the role of p14ARF in MycER TAM WI38 fibroblast due to limited amounts of cells. From these experiments we conclude that p14ARF does not play a major role for stabilization of p53 in response to Myc and E2F1 activation in human fibroblasts.
Myc and E2F1 induce p53 phosphorylation
p53 is phosphorylated at several N-terminal serine (Ser) residues in response to cellular stress signalling (for a review see, Vousden, 2002) . Phosphorylation of Ser-15 and Ser-20 seems to reduce the interaction of p53 with MDM2 and is thus critical for triggering p53 accumulation (Shieh et al., 1997; Chehab et al., 1999) . The ataxia telangiectasia-mutated (ATM) and ATM-and Rad3-related (ATR) kinases that are activated in response to DNA damage are known to phosphorylate p53, either directly or through activation of the Chk1 or Chk2 kinases (Vousden, 2002) . To investigate p53 phosphorylation status following Myc and E2F1 activation, MycER NHFs, MycER TAM WI38, and ER TAM -E2F1 WI38 cells were treated with E2/4-HT for 24 h and double stained with a monoclonal antibody that recognizes phosphoSer-15 p53 along with a polyclonal p53 antiserum that detects the entire p53 pool. Nontreated cells expressed low basal level of total p53 and the background phospho-Ser-15 p53 was at the limit of detection, although a few single positive cells were detected ( Figure  6a, b) . After 24 h of Myc activation the total amounts of p53 increased, but there was also a clear increase in phospho-Ser-15 p53 levels (Figure 6aÀc ). The increase in phospho-Ser-15 p53 levels was also observed in ER TAM -E2F1 WI38 cells and MycER TAM WI38 by Western blotting (Figure 2e, f) . In addition to Ser-15 phosphorylation, we detected an increased phosphorylation of Ser-37 in response to Myc activation, but no significant increase in phosphorylation was observed on residues ser 20 and ser 46 (Figure 6c , left panel) with the antibodies available. As control, we treated normal human fibroblasts with camptothecin (CPT), a topoisomerase inhibitor and DNA double-strand break inducer, or the proteasome inhibitor LLnL. Whereas CPT induced a clear increase in phospho-Ser-15 p53 levels, no such increase was observed in LLnL-treated cells (Figure 6d ).
ATM/ATR inhibitors, caffeine and wortmannin, block p53 accumulation in response to Myc and E2F1
To examine the role of ATM/ATR for p53 phosphorylation in response to Myc and E2F1 activation, we tested the effects of caffeine, an inhibitor of the ATM/ ATR kinases (Blasina et al., 1999; Sarkaria et al., 1999) on Myc and E2F1-induced phosphorylation and accumulation of p53. Continuous treatment of cells with caffeine prevented Myc-induced Ser-15 phosphorylation and p53 accumulation up to 24 h after addition of E2 (Figure 6e, left panel) . Next, we performed a dose titration with caffeine and evaluated p53 levels at an early time point (8 h). In this setting, pre treatment with caffeine at a concentration of 0.3 mm inhibited p53 accumulation in response to Myc activation (Figure 6f) . Treatment with wortmannin, another inhibitor of ATM/ ATR kinases (Sarkaria et al., 1998) , at a concentration of 10 mm also prevented p53 phosphorylation and accumulation (Figure 6e, right panel) . Furthermore, blocking p53 accumulation with caffeine or wortmannin also prevented induction of the MDM2 protein (Figure 6e) . Similarly, treatment of ER TAM -E2F1 WI38 fibroblasts with 3 mm caffeine partially blocked p53 accumulation, despite induction of p14ARF (Figure 6g ). Finally, we used a substrate antibody raised against phosphorylated epitopes corresponding to the ATM/ ATR kinase motif. Immunofluorescence analysis showed that Myc and E2F1-expressing fibroblasts displayed strong staining intensity when compared to age-matched control fibroblasts, arguing that the ATM/ATR kinases are activated in response to Myc and E2F1 activation in human fibroblasts (Figure 6h ). These results demonstrate that Myc and E2F1 activation stimulates phosphorylation of p53 in human fibroblasts.
Discussion
Studies in mouse fibroblasts have demonstrated that induction of p53 in response to activated oncogenes like E1A, Ras, Raf, v-abl, b-catenin, E2F1, and c-Myc involves the p19ARF protein that binds and inhibits MDM2 (Sherr, 1998) . However, much less is known about the role of p14ARF as regulator of p53 in human cells. We asked whether p14ARF was involved in the p53 response to activated Myc or E2F1 in human fibroblasts carrying MycER or ERE2F1 fusion constructs. In MycER NHFs, activation by E2 induces p53 accumulation and activation of the p53 target genes p21 and MDM2, with subsequent cell cycle arrest in G2/M, whereas activation of Myc in WI38 fibroblasts results in apoptosis (Felsher et al., 2000; Hirst and Grandori 2000 and this study). Cell cycle arrest in MycER NHFs was associated with frequent aneuploidy, presumably as a result of inappropriate reinitiation of DNA synthesis (Felsher and Bishop, 1999; Felsher et al., 2000) . Human fibroblasts overexpressing E2F1 arrest mainly in the G1 phase of the cell cycle in a p53-dependent manner and eventually undergo cell death or become senescent (Dimri et al., 2000; Muller et al., 2001; Lomazzi et al., 2002; Nahle et al., 2002) .
We first noted that the kinetics of p53 protein stabilization and activation of downstream target genes in MycER NHFs and WI38 fibroblasts appeared similar to that observed in MEFs . However, our examination of mRNA and protein at several time points after Myc activation in both NHFs and WI38 failed to reveal any significant upregulation of p14ARF. We did not observe any clear increase in p14ARF mRNA by RT-PCR or Northern blotting in MycER NHFs, whereas p14ARF was induced upon E2F1 p14ARF-independent induction of p53 by Myc and E2F1 MS Lindström and KG Wiman activation in fibroblasts carrying an ER TAM -E2F1 fusion protein. Likewise, Western blotting failed to detect any increased p14ARF protein expression. p14ARF is not an abundant protein in human fibroblasts Lindstro¨m et al., 2000; Wei et al., 2001) . One possible reason for the lack of detectable induction of p14ARF protein could be insufficient sensitivity of the monoclonal and polyclonal antibodies used. However, this seems unlikely for several reasons. We have for instance used a cocktail of monoclonal antibodies that individually recognize the protein perfectly well in several human tumor cell lines, including those with relatively low levels of expression. All antibodies also recognize ectopically expressed p14ARF as well as endogenous p14ARF induced by E2F1 in WI38 fibroblasts.
Our conclusion that p14ARF is not critical for the p53 response to Myc activation in NHFs was further Figure 6 MycER activation induces p53 phosphorylation. (a, b) MycER TAM WI38 or MycER NHFs grown in full-growth medium were activated with E2 and double stained with a monoclonal antibody that recognizes phosphorylated Ser-15 p53 (green) and the polyclonal FL393 p53 antibody (red). Noninduced cells had low basal levels of total p53 and the Ser-15 p53 staining was at the limit of detection. At 24 h after MycER activation, both total p53 and phospho-Ser-15 p53 staining intensity was strongly increased. (c) Western blotting demonstrated a strong increase in phosphorylation at Ser-15 and Ser-37 p53 in MycER NHFs 24 h after Myc activation. (d) CPT, but not the proteasomal inhibitor LLnL, induced Ser-15 p53 phosphorylation in NHFs. Both CPT and LLnL caused accumulation of total p53. (e, left panel) MycER NHFs were activated with 1 mm E2 in the presence or absence of 3 mm caffeine (C) and harvested after 24 h. Whole-cell lysates were prepared and p53, MDM2, and p53 phospho-Ser-15 levels were detected by Western blotting. (e, right panel) Wortmannin (W) at a concentration of 10 mm partially prevented p53 accumulation, MDM2 induction, and Ser-15 phosphoylation in MycER NHFs. (f) MycER NHFs were activated with E2 (1 mm) pretreated for 3 h using caffeine at different doses ranging from 0 to 3 mm, and analysed for total p53 expression after 8 h. The p53 blot was exposed longer than usual in order to visualize differences in protein levels. (g) p14ARF was not required for full p53 induction in ER TAM -E2F1 WI38 cells. Cells were activated with 300 nm 4-HT in the presence or absence of 3 mm caffeine and analysed for p53 and p14ARF expression after 24 h by Western blotting. (h) Staining of pBabe NHFs, MycER NHFs, and ER TAM -E2F1 WI38 cells using an antibody that recognizes ATM/ATR-phosphorylated proteins. The FITC signal (green) was merged with nuclear Hoechst 33258 staining (blue). Strong reactivity was observed in a subset of MycER NHFs and ER TAM -E2F1 WI38 cells but not in control NHFs. A strong signal in a cytoplasmic compartment was observed in all human fibroblasts studied irrespective of passage or Myc/E2F1 activation. Original magnification is Â 63 in (a), (b) and (f).
p14ARF-independent induction of p53 by Myc and E2F1
MS Lindström and KG Wiman supported by our experiments with p14ARF siRNA. Silencing of p14ARF did not have any marked effect on the accumulation of p53 after Myc activation. A minor role for p14ARF in potentiating full p53 activity after Myc activation cannot be entirely excluded until experiments have been performed with genetically modified human fibroblasts that strictly lack p14ARF, since silencing of p14ARF using siRNA in our fibroblasts was not complete. In contrast to activation of Myc, E2F1 activation resulted in a clear induction of p14ARF mRNA and protein. Nevertheless, p14ARF siRNA treatment of ER TAM -E2F1 WI38 cells did not have any major effect on the stabilization of p53 upon E2F1 activation, although we cannot exclude that complete p14ARF silencing might have produced a more pronounced effect. Caffeine treatment of E2F1-expressing WI38 fibroblasts partially blocked p53 accumulation despite a significant increase in endogenous p14ARF. Moreover, even though ER TAM -E2F1 WI38 cells appeared p14ARF-positive, a subset remained p14ARF-negative but stained positive for p53. Taken together, these results clearly indicate that p14ARF-independent mechanisms of p53 induction in response to E2F1 activation are predominating. In agreement with this notion, studies in other model systems have demonstrated that mouse p19ARF is not always required for activation of p53 upon E2F1 activation (Rogoff et al., 2002; Russell et al., 2002; Tolbert et al., 2002; Tsai et al., 2002) .
The lack of an apparent key regulatory role for p14ARF in stabilization of p53 upon Myc and E2F1 activation in human fibroblasts raises the question as to other possible mechanisms. It is known that p53 is phosphorylated at several N-terminal Ser residues upon DNA damage, including Ser-15 and Ser-20 (Prives, 1998) . Phosphorylation of Ser-15 and Ser-20 leads to increased transcriptional transactivation efficiency, decreased MDM2 binding, and reduced nuclear export. A novel nuclear export signal (NES) has been identified in the p53 N-terminus (Zhang and Xiong, 2001 ). Ser-15 phosphorylation blocks this NES, allowing nuclear p53 accumulation. Thus, N-teminal phosphorylation may trigger p53 accumulation through multiple mechanisms. We therefore tested whether Myc and E2F1 activation triggered N-terminal p53 phosphorylation as a mechanism to induce p53 levels. Our results demonstrate that particularly Ser-15 is phosphorylated after Myc activation, but we also observed increased phosphorylation of Ser-37. We failed to detect any significant de novo increase in phosphorylation at serine residues 20 and 46 of p53 with the specified antibodies. We also found that E2F1 induced p53 phosphorylation of Ser-15, consistent with previous studies (Rogoff et al., 2002; Russell et al., 2002) .
Our findings indicate that p53 accumulation in response to Myc and E2F1 activation occurs through mechanisms similar to those responsible for p53 induction upon DNA damage. This is in agreement with recent studies showing that Myc or E2F1 activation induces DNA damage in a cell cycle-independent manner in part through induction of reactive oxygen species (ROS) (Tanaka et al., 2002; Vafa et al., 2002) . The exact mechanism by which Myc and E2F1 activation leads to phosphorylation of p53 remains unclear. Several kinases are known to phosphorylate p53 upon DNA damage, including ATM, ATR, Chk1, and Chk2 (Abraham 2001; Vousden, 2002) . E2F1 induces ATM by direct activation of the ATM promotor (Berkovic and Ginsberg, 2003) , whereas stabilization and phosphorylation of p53 at Ser-15 in response to Cyclin E overexpression is both ATM and p14ARF-independent (Minella et al., 2002) . It is conceivable that Myc and also E2F1 induces ATM/ ATR through oxidative stress and generation of DNA strand breaks, in addition to possible DNA replication errors during S phase. Our finding that caffeine and wortmannin, both inhibitors of the ATM and ATR kinases (Sarkaria et al., 1998 (Sarkaria et al., , 1999 Blasina et al., 1999; Hall-Jackson et al., 1999; Zhou et al., 2000) , prevented p53 Ser-15 phosphorylation upon Myc or E2F1 activation suggests that ATM (or ATR) is the critical kinase. This notion is supported by the fact that Myc and E2F1-expressing fibroblasts showed high reactivity with an antibody recognizing phosphorylated ATM/ATR kinase substrates compared with control fibroblasts at the same passage. It should be emphasized that caffeine might act as an antioxidant that could scavenge ROS and thus indirectly reduce oxidative stress-induced DNA damage (Devasagayam et al., 1996; Lee, 2000) . Moreover, continuous exposure to caffeine was shown to inhibit the proliferation of NHFs in a dose-dependent manner (Deplanque et al., 2000) suggesting that caffeine also could interfere with Myc and E2F1-induced DNA replication. Such poorly characterized properties of caffeine could all contribute to the decreased p53 phosphorylation and stabilization observed in the experimental systems described here and elsewhere. RNA interference strategies targeting ATM/ATR kinases will hopefully clarify these issues.
We do not want to exclude the interesting possibility that Myc and E2F1 may trigger p53 through other pathways than ROS-mediated DNA damage or premature S phase entry followed by dysregulated DNA replication. A recent study indicated that ATM can be activated by changes in chromatin in the absence of DNA damage (Bakkenist and Kastan, 2003) . Since Myc may modify chromatin (for a review see, Eisenman, 2001) , ATM activation and p53 phosphorylation in our fibroblasts could be due to chromatin changes rather than DNA damage. Indeed, we have not observed frequent focus formation of DNA damage checkpoint proteins Mre11, H2AX, and Chk2 in MycER NHFs despite accumulation of p53 (M Lindstro¨m, unpublished observations). Furthermore, unrestrained Myc-induced cell growth could result in a 'nucleolar stress' response due to altered ribosome biogenesis (Ruggero and Pandolfi, 2003) , leading to activation of p53 through upregulation of certain nucleolar proteins. Indeed, B23/ nucleophosmin has recently been shown to induce p53 when overexpressed in human fibroblasts (Colombo et al., 2002) . In this context, it is noteworthy that mouse p14ARF-independent induction of p53 by Myc and E2F1 MS Lindström and KG Wiman p19ARF was shown to inhibit ribosomal rRNA processing independently of p53 (Sugimoto et al., 2003) . Thus, we envisage that p19ARF could in fact interfere with Myc's growth-stimulating activities through this mechanims in settings where p19ARF is strongly induced by Myc, for example, MEFs and mouse B cells Eischen et al., 1999) .
In conclusion, we show that p14ARF does not play any major role for p53 stabilization in response to Myc or E2F1 activation in human fibroblasts. Instead, Myc and E2F1 cause N-terminal p53 phosphorylation, mimicking the effect of DNA damage. Thus, the p53 response to activated oncogenes in human cells appears more complex than suggested by previous studies in MEFs, and clearly involves p14ARF-independent pathways.
Materials and methods
Cell culture
Normal human diploid fibroblasts derived from foreskin, henceforth denoted NHF, expressing pBabe-MycER, pBabe MycER together with pBabe-E6, or empty pBabe vector were originally from Michael J Bishop and Dean W Felsher (Stanford University, Stanford, CA, USA) and provided by Anders Zetterberg (Karolinska Institute, Stockholm, Sweden) and has been described and characterized (Felsher and Bishop, 1999; Felsher et al., 2000) . Normal human diploid fibroblasts were from Coriell cell repositories (Coriell Institute for Medical Research, Camden, NJ, USA). WI38 human diploid lung embryonic fibroblasts (passage 9) and WI38 pool infected with retrovirus encoding MycER TAM (Hirst and Grandori, 2000) were obtained from Carla Grandori (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). WI38 fibroblasts (passage 9) expressing pBabe ER TAM -E2F1 (Vigo et al., 1999; Muller et al., 2001) were provided by Kristian Helin (European Institute of Oncology, Milan, Italy) All fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM), 10% FBS, 2mM l-glutamine at 371C with 5% CO2 in humidified air. Experiments were carried out with polyclonal cell pools initially selected and expanded for 2-3 passages in puromycin. Freshly thawed cells from the same passage were allowed to recover for at least 72 h before starting each experiment. To activate Myc or E2F1, the cells were treated with E2 at a concentration of 1 mm or 4-HT at 300 nm as indicated. E2 and 4-OHT were from Sigma-Aldrich, Sweden. Western blotting and immunostaining confirmed expression of fusion proteins. We used the cervical carcinoma line HeLa, lung adenocarcinoma cell line H1299 (both strongly p14ARF positive), osteosarcoma lines U2OS (p14ARF protein negative), p19ARFÀ/À MEFs, Saos-2 (p14ARF positive), and Burkitt lymphoma (BL) lines BL2, as controls in PCR, Western and immunostainings (see also Lindstro¨m et al., 2001) .
Drug treatment
Wortmannin (Sigma) was dissolved in Me 2 SO as a 10 mm stock and stored at À201C. Caffeine (Sigma) was directly dissolved in cell medium at a final concentration of 0.1-10 mm as indicated. The protein synthesis inhibitor cycloheximide (Sigma) was diluted in ethanol and used at a final concentration of 50 mg/ml. The DNA damaging agent CPT (Sigma) dissolved in diH2O at a stock concentration of 10 mm were used at a final concentration of 2 mm. Proteasome inhibitor LLnL prepared as 20 mm stock was purchased from Boehringer-Mannheim (Germany) and was used for p53 stabilization experiments. Cells were treated with drugs as indicated and viability was assessed by trypan blue exclusion and visual inspection of the cell cultures. For analysis of proliferation and senescence in the cell cultures, we regularly used the BrdU incorporation assay as described (Hashemi et al., 2002) and senescense associated b-gal (SA-b-gal) staining as outlined by Wei and Sedivy (1999) . Cells were photographed using a Nikon Coolpix 990 Digital Camera (Nikon Corp. Japan).
RT-PCR and Northern blotting
Total RNA was isolated from subconfluent cultures by using Trizol reagent (Invitrogen Life Technologies, Groningen, The Netherlands). RNA yields were determined by duplicate absorbance measurements and RNA integrity was verified by agarose gel electrophoresis. Semiquantitative RT-PCR was performed using the AdvantageTM RT-PCR kit according to the manufacturer's instructions (Clontech, Becton-Dickinson Biosciences, Palo Alto, CA, USA). We used 200 ng of total RNA for cDNA synthesis. A volume of 1 ml from each batch of cDNA diluted to 50 ml was used in subsequent PCR. We also used the Titanium One-Step RT-PCR kit (Clontech) with equivalent results as with the Advantage TM RT-PCR kit. p53 and b-actin primers were from Clontech and designed as follows for p53: b-actin was usually amplified for 24 cycles, p53 and p14ARF for at least 28 and 32 cycles, respectively. The approximative linear range of amplification was tested using four cycle intervals between 16 and 36 cycles and different amounts of starting cDNA. PCR products of the size of 371 bp (p53), 838 bp (b-actin) and 412 bp p14ARF) were run on a 1.1% agarose gels and analysed using the Gel-Doc digital gel documentation system and software package (Bio-Rad, Stockholm, Sweden). For Northern blotting, 10 mg of total RNA was electrophoresed on a 1.2% formaldehyde-agarose gel and transferred onto Nylon Hybond-N þ membranes (Amersham Biosciences, Uppsala, Sweden) using standard methods. Probes were labelled by random priming of gel-purified cDNA fragments (Rediprime II labelling kit; Amersham Biosciences). p14ARF exon 1b was amplified with PCR using the following primers 5 0 -AAGAATTCATGGTGCGCAGGTTCTTGG-3 0 and 5 0 -AAGGATCCTATGGTCTTCTAGGAAGCGGGCT-3 0 . Blocking was performed overnight followed by incubation with the radioactive probe for another 24 h. Filters were washed twice in 0.1% SSC, 0.1% SDS solution. The radioactive signal was detected using a PhosphoImager FLA-3000 reader (Fujifilm, Solna, Sweden) and analysed using Image p14ARF-independent induction of p53 by Myc and E2F1Gauge ver. 3.12 analysis software software (Fuji). Myc can induce alterations in cell growth and morphology, as well as general changes in protein translation (Shiio et al., 2002; Gomez-Roman et al., 2003) . We used b-actin and the 28S/18S as controls for protein and RNA content throughout this study. Protein and RNA concentrations were also measured by spectrophotometer and the levels of b-actin and 28S/18S correlated with the amounts estimated using a spectrophotometer, at least up to 48 h after Myc activation.
Flow cytometry
Adherent cells were trypsinized and washed once in PBS. Cells were then fixed in ice-cold EtOH and stored overnight at þ 41C, washed in PBS and finally incubated in 100 ml FACS buffer (Propidium iodide and RNase A in PBS) for 30 min at þ 371C. Cells were then stored at þ 41C until analysis. Measurements were performed on a FACS Calibur (Becton Dickinson, Stockholm, Sweden). Analysis was done using the Cell Quest software (BD Biosciences).
RNA interference
Fluorescein-labelled siRNA oligos were purchased from Xeragon Inc. (Qiagen-Xeragon, Germantown, MD, USA). All siRNA transfections were performed with the Oligofectamine reagent following the manufacturer's advice (Invitrogen). Cells were seeded in six-well plates and incubated with mixtures of Oligofectamine (4 ml/well) and FITClabelled siRNA oligo (no more than 0.5 mg/well) diluted in Optimem (Invitrogen). After 6 h, the fresh medium containing serum and antibiotics was added, but the transfection mixtures were not removed. Cells were analysed by immunofluorescence and Western blotting 48 h after transfection to evaluate silencing of p14ARF. Myc and E2F1-expressing cells were transfected 12 h before addition of hormone and analysed after 48 h.
Antibodies
The following antibodies have been used for immunofluorescence and Western blotting: rabbit polyclonal antiserum 271 against human p14ARF (Lindstro¨m et al., 2000) , mouse monoclonals anti-p14ARF clone 14P02 (DCS270, lot 850P109), and 14P03 (DCS271, lot 1115P005) (Neomarkers/ Labvision, Fremont, CA, USA); rabbit polyclonal antip19ARF antibody (ab80, Abcam Ltd, Cambridge, UK); anti-MDM2 (clone SMP14, Neomarkers); anti-MDM2 (clone 2A10 from Dr AJ Levine, The Rockefeller University, USA); rabbit polyclonal anti-MDM2 (N20, Neomarkers); mouse monoclonal anti-p53 (clones DO-1 and DO-7, Oncogene Res. Products, Boston, MA, USA); rabbit polyclonal anti-p53 (FL393, Santa Cruz); anti-B23/NPM nucleolus marker (from Dr PK Chan, Baylor College, USA); rabbit polyclonal anti-p16INK4a (C20, Santa Cruz); mouse monoclonal anti-p16INK4a (DCS-50, Neomarkers); mouse monoclonal anti-p21 (Transduction Laboratories, Lexington, KY, USA); mouse monoclonal anti-b-actin (clone AC-15, Sigma); mouse monoclonal anti-BrdU (clone BRD2, Neomarkers); mouse monoclonal anti-E2F1 (clone KH95, Kristian Helin, Milan, Italy); mouse monoclonal anti-myc (clone 9E10, Santa Cruz); and rabbit polyclonal anti-myc (N-262, Santa Cruz). For examination of p53 phosphorylation, we used the 16G8 mouse IgG1 anti-phosphoserine 15 monoclonal antibody (#9286, Lot 2, Cell Signaling Technology Inc., Beverly, MA, USA) and rabbit polyclonal anti-phosphoserine 15 p53 (#9284, Lot 4). In addition, rabbit polyclonal antibodies towards p53 phosphoserine residues 20 (Lot 2), 37 (Lot 2) and 46 (Lot 1) were used (Cell Signaling). A rabbit polyclonal phospho-(Ser/ Thr) ATM/ATR substrate antibody (#2851, Lot 1, Cell Signalling) that detects endogenous levels of proteins phosphorylated at the motif L(S*/T*)Q was used for immunofluorescence. Horse anti-mouse antibodies and goat anti-rabbit Ig antibodies conjugated with Texas Red, AMCA, or FITC (Vector, Burlingame, CA, USA) were used as secondary antibodies.
Immunofluorescence
Cells were fixed with methanol-acetone (1 : 1) at À201C for at least 10 min and rehydrated in PBS for 15 min at room temperature. Antibodies were diluted in blocking buffer (2% BSA, 0.2% Tween-20, 10% glycerol in PBS). The primary antibodies were incubated with the cells for 60 min at room temperature followed by three washes in PBS. The secondary fluorochrome-conjugated antibodies were diluted in blocking buffer and incubated with the cells for an additional 45 min. To detect nuclei, Hoechst 33258 (Sigma) was added at a final dilution of 40 ng/ml. After three PBS washes, the slides were mounted with Vectashield anti-fading agent (Vector). Glass slides were analysed using a Leitz DM RB microscope equipped with Plan-Apochromat 63 Â /1.32 and Plan-Fluotar 100 Â /1.3-0.6 objectives. Alternatively, we also used a (3D) Zeiss Axioplan II microscope controlled by Axiovision 3.1 software and equipped with Plan-Apochromat 63 Â /1.4 and Plan-Neofluar 100 Â /1.30 objectives. Images were assembled in Adobe Photoshop 6.0. Original image captures and antibody dilutions are available upon request.
Western blotting
Western blotting was performed as described (Hashemi et al., 2002) . Briefly, whole-cell extracts were prepared by scraping cells into lysis buffer (2% SDS, b-mercaptoethanol, 10% glycerol, 60 mm Tris pH 6.8 in dH 2 O) and boiled for 5 min. Equal amounts of protein were usually estimated by Bradford assays (without b-mercaptoethanol added to the lysis buffer). Proteins were separated on SDS polyacrylamide gels and transferred to nitrocellulose membranes (Amersham). Blocking and incubation with primary and secondary antibodies were performed in 5% milk (1% for antibodies) in PBS. Chemiluminescent Western blotting was performed using a Luminescent Image Analyzer, LAS 1000 plus (Fuji). Image densitometry was done using Image Gauge ver. 3.12 analysis software (Fuji).
